Selinexor after CAR-T for high-risk multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if the drug selinexor can help prevent multiple myeloma from coming back after CAR-T cell therapy. It is for people with high-risk or persistent myeloma who have already received a specific CAR-T treatment called Carvykti.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is considered high-risk or that is still detectable after CAR-T therapy.
- You have already received the CAR-T treatment called ciltacabtagene autoleucel (Carvykti).
- You are at least 18 years old.
- You are in fairly good health, able to do most daily activities (ECOG score 0-2).
- Your blood counts, liver, and kidneys are working well enough for the study.
- You do not have active cancer in the brain or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This Phase 2 trial studies a treatment called SVRd in people newly diagnosed with multiple myeloma that has spread to areas outside the bone (called extramedullary disease). It aims to see how well the treatment works and whether it is safe for this specific group.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.